KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Assets (2017 - 2026)

Amneal Pharmaceuticals has reported Other Non-Current Assets over the past 9 years, most recently at $57.8 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 3.87% year-over-year to $57.8 million; the TTM value through Dec 2025 reached $57.8 million, down 3.87%, while the annual FY2025 figure was $57.8 million, 3.87% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $57.8 million at Amneal Pharmaceuticals, up from $39.5 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $108.3 million in Q3 2022 and troughed at $19.2 million in Q2 2021.
  • A 5-year average of $59.7 million and a median of $59.0 million in 2024 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: soared 454.39% in 2022 and later plummeted 59.26% in 2024.
  • Year by year, Other Non-Current Assets stood at $20.6 million in 2021, then soared by 400.71% to $103.2 million in 2022, then tumbled by 46.21% to $55.5 million in 2023, then increased by 8.31% to $60.1 million in 2024, then fell by 3.87% to $57.8 million in 2025.
  • Business Quant data shows Other Non-Current Assets for AMRX at $57.8 million in Q4 2025, $39.5 million in Q3 2025, and $44.8 million in Q2 2025.